Wednesday January 18th, 2017

A diagnostic test for lung cancer detects genetic alterations which may remain hidden when conventional techniques are used

A study led by researchers from Hospital Clínic-IDIBAPS, in collaboration with Dexeus University Hospital, shows the effectiveness of a new genetic test for molecular diagnosis in lung cancer. This is the first time that a test for this type of tumor is implemented in clinical practice. It consists of analyzing three genes with an innovative genomic technology that allows detecting multiple alterations which may not be identified when conventional diagnostic techniques are used. If these genetic alterations are detected, the patient can be treated with an oral drug that has minimal toxicity and a very high clinical benefit. The study has been coordinated by Dr. Noemí Reguart, an oncologist at the Hospital Clínic-IDIBAPS, and Dr. Aleix Prat, head of the Clinical Oncology Department and of the IDIBAPS research team on Translational Genomics and directed therapies in solid tumors.

Lung cancer is the leading cause of cancer death worldwide and, in Spain, is the third most common tumor. In 70% of the cases the disease is diagnosed in very advanced stages, since it does not shows symptoms. In the last 10 years different molecular markers have been identified, opening the door to the development of targeted therapies for this type of cancer. This is the case of the genes named ALK, Ros1 and RET. Patients who have alterations in these genes may benefit from individualized and oral-administered biological drugs that improve clinical outcomes over conventional chemotherapy.

Thus far, genetic alterations were detected individually by conventional histopathological techniques that require analyzing each alteration individually and with a certain degree of subjectivism. Since the amount of sample that can be extracted from the lung in a biopsy is very limited, alternative modalities of analysis are required to detect multiple alterations at the same time.

In the article, published in the journal Clinical Chemistry, researchers have validated the capacity of a genomic platform to detect alterations in three genes and have apply it in clinical practice. To do this, they have compared the tumor data obtained by gene expression (nCounter of Nanostring) with the conventional histopathological data. The advantage of this new technology is that it requires much less sample to do the analysis, that it is faster and more objective in obtaining the results and that it detects more than 50 possible alterations in the three genes which sometimes remain hidden when current microscopy techniques are used.

This way, tumors that previously resulted negative for these alterations, now could be positive. This has a very important implication in the clinical practice, because if these alterations are present they can be inhibited with a specific treatment orally administrated which improves survival and quality of life for patients. The alternative if the test is not performed is chemotherapy“, explains Dr. Noemí Reguart. “At the moment we have validated a test with three genes, and soon we will add 7 more,” she adds.

Dr. Aleix Prat concludes that, “this study takes a very important step towards personalized or precision medicine in lung cancer. At our hospital we have the technology and the test to carry out these analyses routinely in the clinical practice in all patients with advanced lung cancer.”

Article reference:

Identification of ALK, ROS1 and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non–Small-Cell Lung Cancer Patients

Noemí Reguart, Cristina Teixidó, Ana Giménez-Capitán, Laia Paré, Patricia Galván, Santiago Viteri, Sonia Rodríguez, Vicente Peg, Erika Aldeguer, Nuria Viñolas, Jordi Remon, Niki Karachaliou, Esther Conde, Fernando Lopez-Rios, Ernest Nadal, Sabine Merkelbach-Bruse, Reinhard Büttner, Rafael Rosell, Miguel A. Molina-Vila, Aleix Prat

DOI: 10.1373/clinchem.2016.265314 Published January 2017

Share or bookmark this post

  • Delicious
  • Facebook
  • Twitter
  • email
  • LinkedIn
  • StumbleUpon

    Comments are closed.